feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2026 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / New TB Vaccine Promises Hope Against Deadly Disease

New TB Vaccine Promises Hope Against Deadly Disease

25 Nov, 2025

•

Summary

  • A new HSP Subunit Vaccine is nearing commercial availability.
  • Existing vaccines are largely ineffective for adult TB prevention.
  • IIT Bhubaneswar and ILS Bhubaneswar developed the novel vaccine.
New TB Vaccine Promises Hope Against Deadly Disease

A new generation HSP Subunit Vaccine, designed to combat Mycobacterium tuberculosis, is approaching commercial availability. Developed through collaborative research between the Indian Institute of Technology (IIT) Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar, this vaccine addresses the critical gap in preventing pulmonary tuberculosis in adolescents and adults.

The existing Bacillus Calmette Guérin (BCG) vaccine, over a century old, provides only limited protection to infants and is largely ineffective in older age groups. Tuberculosis remains a significant global health threat, with the WHO reporting 1.23 million deaths in 2024 alone, underscoring the urgent need for improved prevention strategies.

TechInvention Lifecare Limited has entered into a license agreement for the technology transfer and commercialization of this novel vaccine. This partnership aims to efficiently translate the indigenous vaccine technology from research to product development and eventual market availability, marking a significant step forward in India's efforts to control the TB epidemic.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
The new HSP Subunit Vaccine was jointly developed by IIT Bhubaneswar and the Institute of Life Sciences (ILS) Bhubaneswar.
The BCG vaccine is over a century old, offers limited protection to infants, and is largely ineffective against pulmonary TB in adolescents and adults.
The HSP Subunit Vaccine is expected to be commercially available soon following a licensing agreement.

Read more news on

Healthside-arrow
trending

Justice Dept. Epstein files access

trending

ACC drops German gigafactory

trending

House of the Dragon vs Thrones

trending

Ola Uber Rapido strike

trending

Afghanistan spin threatens New Zealand

trending

Barcelona vs Mallorca live stream

trending

Harley-Davidson cheaper in India

trending

Anaswara Rajan stars With Love

trending

ISL 2025/26 fixtures announced

You may also like

Guinea-Bissau Halts US-Funded Infant Vaccine Study

22 hours ago • 4 reads

article image

Covid Jabs & Fertility: New Study Debunks Myth

5 Feb • 14 reads

article image

China Approves First Homegrown Subunit Flu Vaccine

2 Feb • 24 reads

article image

AAP Challenges CDC on Crucial Vaccine Guidance

27 Jan • 70 reads

UK Kids Unvaccinated: 1 in 5 Miss Deadly Disease Protection

1 Jan • 228 reads

article image